Will Venetoclax Become The New Standard? [MDS Professional Report]

We will discuss the addition of venetoclax to hypomethylating agents in the treatment of advanced myeloid neoplasms, especially higher-risk myelodysplastic syndromes.We will then report a study testing the efficacy and safety of imetelstat, a new telomerase-inhibitor, in the treatment of patients with lower-risk MDS and anemia following ESA failure.We will then review an interesting therapeutic approach to improve or restore erythroid response by adding lenalidomide to MDS patients treated with erythropoietin but lost the response.Finally, we will return to the "hot" topic of targeting the TP53 mutation, by summarizing an important clinical trial using a TP53 activator.

You can listen to Will Venetoclax Become The New Standard? [MDS Professional Report] online on Radio and Podcast. Open the player on this page to stream the available audio.

Will Venetoclax Become The New Standard? [MDS Professional Report] is an episode from MDS Professional Report by PI Media.

This episode is 34:49 long.

This episode was published on Jun 2, 2021.

Yes. Use the heart button on the episode page to add it to your favorite episodes list.

Yes. This page shows related episodes from MDS Professional Report when more episodes are available from the podcast feed.